

# Technical Data Sheet

## BUV615 Mouse Anti-Human CD196 (CCR6)

### Product Information

Material Number:	751515
Size:	50 µg
Clone:	11A9
Alternative Name:	BN-1; C-C CKR-6; C-C chemokine receptor type 6; CC-CKR-6; CCR-6
Reactivity:	Human (Tested in Development)
Isotype:	Mouse IgG1, κ
Immunogen:	Human CD196/CCR6 Peptide
Application:	Flow cytometry (Qualified)
Concentration:	0.2 mg/ml
Entrez Gene ID:	1235
Storage Buffer:	Aqueous buffered solution containing ≤0.09% sodium azide.
Regulatory Status:	RUO

### Description

The 11A9 monoclonal antibody specifically binds to CD196, which is also known as CCR6. CCR6 is a seven-transmembrane, G-protein-coupled, glycoprotein receptor that is a member of the beta chemokine receptor family. The human CCR6 gene has been mapped to chromosome 6q27. CCR6 is a receptor for the CC chemokine CCL20/MIP-3alpha/LARC/Exodus and also binds with lower affinity to and mediates responses to beta-defensin2/hBD-2. CCR6 is predominantly expressed by B lymphocytes, certain subsets of effector and memory T cells and by immature dendritic cells but not by monocytes, NK cells, or granulocytes. Skin-homing CLA (Cutaneous Lymphocyte Antigen)-positive memory T cells, Th1 cells, regulatory T cells and IL-17A-producing Th17 cells predominantly express high levels of CCR6. CCR6 mediates the trafficking of T, B, and dendritic cells to epithelial sites near the skin and mucosal surfaces during inflammatory and immunological responses. An N-terminal peptide of human CCR6 was used as an immunogen to generate the 11A9 hybridoma. The 11A9 antibody does not cross-react with human CCR1, CCR2, CCR3, CCR4, CCR5, CCR7, CCR8, CCR9, CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 receptors. This antibody is NOT a neutralizing antibody.

The antibody was conjugated to BD Horizon BUV615 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome with an Ex Max near 350 nm and an Em Max near 615 nm. BD Horizon Brilliant BUV615 can be excited by the ultraviolet laser (355 nm) and detected with a 610/20 filter and a 595 nm LP. Due to the excitation of the acceptor dye by the blue/yellow-green laser line, there may be significant spillover into channels detecting PE-CF594 like emissions (eg, 610/20-nm filter).

### Preparation and Storage Section

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.

### Recommended Assay Procedure

BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD CompBead to ensure that BD CompBeads are appropriate for your specific cellular application.

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

Note: When using high concentrations of antibody, background binding of this dye to erythroid cell subsets (mature erythrocytes and precursors) has been observed. For researchers studying these cell populations, or in cases where light

scatter gating does not adequately exclude these cells from the analysis, this background may be an important factor to consider when selecting reagents for panel(s).

## Suggested Companion Products

Catalog Number	Name	Size	Clone
554656	Stain Buffer (FBS) RUO	500 mL	
554657	Stain Buffer (BSA) RUO	500 mL	
563794	Brilliant Stain Buffer RUO	100 Tests	
555899	Lysing Buffer RUO	100 mL	
566349	Brilliant Stain Buffer RUO	1000 Tests	
566385	Brilliant Stain Buffer Plus RUO	1000 Tests	
349202	Lysing Solution 10X Concentrate CE/IVD	100 NA	
612986	BUV615 Mouse IgG1, $\kappa$ Isotype Control RUO	50 $\mu$ g	
564219	Human BD Fc Block™ RUO	50 $\mu$ g	

## Product Notices

1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at [www.bdbiosciences.com/colors](http://www.bdbiosciences.com/colors).
6. Please refer to [www.bdbiosciences.com/us/s/resources](http://www.bdbiosciences.com/us/s/resources) for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to <http://regdocs.bd.com> to access safety data sheets (SDS).
9. CF™ is a trademark of Biotium, Inc.
10. BD Horizon Brilliant Ultraviolet 615 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.

## References

- Baba M, Imai T, Nishimura M, et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. *J Biol Chem.* 1997; 272(23):14893-14898.
- Brandes M, Willmann K, Lang AB, et al. Flexible migration program regulates gamma delta T-cell involvement in humoral immunity. *Blood.* 2003; 102(10):3693-3701.
- Cabezon R, Sintès J, Llinas L, Benitez-Ribas D. Analysis of HLDA9 mAbs on plasmacytoid dendritic cell. *Immunol Lett.* 2011; 134(2):167-173.
- Greaves DR, Wang W, Dairaghi DJ, et al. CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells. *J Exp Med.* 1997; 186(6):837-844.
- Homey B, Dieu-Nosjean MC, Wiesenborn A, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. *J Immunol.* 2000; 164(12):6621-6632.
- Kim CH, Rott L, Kunkel EJ, et al. Rules of chemokine receptor association with T cell polarization in vivo. *J Clin Invest.* 2001; 108(9):1331-1339.
- Liao F, Alderson R, Su J, Ullrich SJ, Kreider BL, Farber JM. STRL22 is a receptor for the CC chemokine MIP-3alpha. *Biochem Biophys Res Commun.* 1997; 236(1):212-217.
- Liao F, Rabin RL, Smith CS, Sharma G, Nutman TB, Farber JM. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. *J Immunol.* 1999; 162(1):186-194.
- Liao F, Shirakawa AK, Foley JF, Rabin RL, Farber JM. Human B cells become highly responsive to macrophage-inflammatory protein-3 alpha/CC chemokine ligand-20 after cellular activation without changes in CCR6 expression or ligand binding. *J Immunol.* 2002; 168(10):4871-4880.
- Lim HW, Lee J, Hillsamer P, Kim CH. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. *J Immunol.* 2008; 180(1):122-129.
- Llinas L, Lazaro A, de Salort J, Matesanz-Isabel J, Sintès J, Engel P. Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry. *Immunol Lett.* 2011; 134(2):113-121.
- Ramos-Medina R, Montes-Moreno S, Maestre L, et al. Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues. *Immunol Lett.* 2011; 134(2):150-156.

Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature*. 1999; 401(6754):708-712.

Thomas SY, Banerji A, Medoff BD, Lilly CM, Luster AD. Multiple chemokine receptors, including CCR6 and CXCR3, regulate antigen-induced T cell homing to the human asthmatic airway. *J Immunol*. 2007; 179(3):1901-1912.

Yang D, Chertov O, Bykovskaia SN, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. *Science*. 1999; 286(5439):525-528.

## BD Biosciences

[bdbiosciences.com](http://bdbiosciences.com)

United States  
877.232.8995

Canada  
888.268.5430

Europe  
32.53.720.550

Japan  
0120.8555.90

Asia Pacific  
65.6861.0633

Latin America/Caribbean  
0800.771.7157



For country contact information, visit [bdbiosciences.com/contact](http://bdbiosciences.com/contact)

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for a patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.  
For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

©2020 BD. All rights reserved. Unless otherwise noted, BD, the BD Logo and all other trademarks are the property of Becton, Dickinson and Company or its affiliates.